- 专利标题: Delivery of RNA to trigger multiple immune pathways
-
申请号: US18065089申请日: 2022-12-13
-
公开(公告)号: US11717529B2公开(公告)日: 2023-08-08
- 发明人: Andrew Geall , Katrin Ramsauer , Gillis Otten , Christian Walter Mandl
- 申请人: GLAXOSMITHKLINE BIOLOGICALS SA
- 申请人地址: BE Rixensart
- 专利权人: GlaxoSmithKline Biologicals SA
- 当前专利权人: GlaxoSmithKline Biologicals SA
- 当前专利权人地址: BE Rixensart
- 代理商 Christopher L. Wright
- 分案原申请号: US13808085
- 主分类号: A61K39/00
- IPC分类号: A61K39/00 ; A61K39/12 ; A61K31/7088
摘要:
RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
公开/授权文献
- US20230114607A1 DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS 公开/授权日:2023-04-13
信息查询